NVO novonordisk.com: Indikator likuiditas cepet

Record cash flows from the sale of obesity and diabetes drugs are creating colossal financial momentum for Novo Nordisk A/S (NVO). Dominance in this niche is sustained by complex peptide production, cementing its status as a global leader. The GURU.Markets platform displays the quick ratio, where 0.64 reflects the latest value of the metric. Business resilience relies on patent protection and support from insurance companies.

The quick ratio is calculated by dividing the sum of cash and accounts receivable by current liabilities. This ratio determines a business's ability to instantaneously settle debts without liquidating inventory. For Novo Nordisk A/S (NVO), with its unique diabetes treatment ecosystem, such resilience confirms financial strength coupled with high patient loyalty. By analyzing the current state of quick liquidity, an investor assesses the company's readiness for macroeconomic shocks.